GoodRx (GDRX) Earnings Date, Estimates & Call Transcripts

$6.66
-0.03 (-0.45%)
(As of 04/22/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 9
Before Market Opens
Confirmed
Actual EPS
(Feb. 29)
$0.02
Consensus EPS
(Feb. 29)
$0.02
Skip Charts & View Estimated and Actual Earnings Data

GDRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

GDRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

GoodRx Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20241$0.04$0.04$0.04 
Q2 20241$0.03$0.03$0.03 
Q3 20241$0.03$0.03$0.03 
Q4 20241$0.02$0.02$0.02 
FY 20244$0.12$0.12 $0.12

GDRX Earnings Date and Information

GoodRx last released its quarterly earnings data on February 29th, 2024. The reported $0.02 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.02. The business earned $196.64 million during the quarter, compared to the consensus estimate of $195.59 million. GoodRx has generated ($0.02) earnings per share over the last year (($0.02) diluted earnings per share). Earnings for GoodRx are expected to grow by 34.78% in the coming year, from $0.23 to $0.31 per share. GoodRx has confirmed that its next quarterly earnings report will be published on Thursday, May 9th, 2024. GoodRx will be holding an earnings conference call on Thursday, May 9th at 8:00 AM Eastern. Interested parties can register for or listen to the call..

GoodRx Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/9/2024
Confirmed)
-------  
2/29/2024Q4 2023$0.02$0.02-$0.10$195.59 million$196.64 million
11/9/2023Q3 2023$0.06$0.06-$0.09$188.52 million$180.00 million    
8/9/2023Q2 2023$0.01$0.02+$0.01($0.10)$186.90 million$189.68 million
5/10/2023Q1 2023$0.01$0.01-$0.03$181.87 million$183.99 million
2/28/2023Q4 2022($0.01)$0.01+$0.02$0.02$178.17 million$184.11 million
8/8/2022Q2 2022($0.02)$0.02+$0.04$0.04$184.71 million$191.80 million    
5/9/2022Q1 2022$0.02$0.03+$0.01$0.03$200.61 million$203.30 million    
2/28/2022Q4 2021$0.03$0.01($0.02)$0.12$217.51 million$213.30 million    
11/10/2021Q3 2021$0.01$0.09+$0.08$0.02$196.08 million$195.10 million    
8/12/2021Q2 2021$0.01$0.08+$0.07($0.07)$174.15 million$176.64 million    
5/13/2021Q1 2021$0.07$0.07-($0.02)$160.61 million$160.40 million  

GoodRx Earnings - Frequently Asked Questions

When is GoodRx's earnings date?

GoodRx has confirmed that its next quarterly earnings data will be published on Thursday, May 9th, 2024. Learn more on GDRX's earnings history.

Did GoodRx beat their earnings estimates last quarter?

In the previous quarter, GoodRx (NASDAQ:GDRX) reported $0.02 earnings per share (EPS) to hit the analysts' consensus estimate of $0.02. Learn more on analysts' earnings estimate vs. GDRX's actual earnings.

How much revenue does GoodRx generate each year?

GoodRx (NASDAQ:GDRX) has a recorded annual revenue of $750.27 million.

How much profit does GoodRx generate each year?

GoodRx (NASDAQ:GDRX) has a recorded net income of -$8.87 million. GDRX has generated -$0.02 earnings per share over the last four quarters.

What is GoodRx's price-to-earnings ratio?

GoodRx (NASDAQ:GDRX) has a forward price-to-earnings ratio of 28.96. The price/earnings-to-growth ratio is 3.67.

What is GoodRx's EPS forecast for next year?

GoodRx's earnings are expected to grow from $0.23 per share to $0.31 per share in the next year, which is a 34.78% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:GDRX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners